M. Jansen et al., EFFECT OF PURINE SYNTHESIS INHIBITION ON WIDR SPHEROIDS IN-VITRO OR ON WIDR OR COLON-38 TUMORS IN-VIVO - COMPLETE GROWTH-INHIBITION BUT NOTREGRESSION, Biochemical pharmacology, 47(6), 1994, pp. 1067-1078
Clinical responses for anticancer agents are based upon tumor regressi
on. We have investigated the potential of glycineamide ribonucleotide
transformylase (GAR TFase) inhibitors to produce regressions in multip
le preclinical models of colon carcinoma. The growth of multicellular
tumor spheroids of WiDr human colon carcinoma was inhibited by the GAR
TFase inhibitors 5-deazaacyclotetrahydrofolate (5-DACTHF), its 2'-flu
oro, 3'-fluoro, 10-deaza, and 10-thia analogs as well as 5,10-dideazat
etrahydrofolate, but none of the compounds caused spheroid regressions
. By contrast, complete spheroid disruption was observed with exposure
to etoposide, m-AMSA (amsacrine), piritrexim, or 2-desamino-2-methyl-
10-propargyl-5,8-dideazafolate (DMPDDF). Light microscopy of the spher
oids treated with either 5-DACTHF or DMPDDF suggested that the reason
for the difference is extensive cell kill throughout the spheroid in t
he presence of DMPDDF compared with little or no kill, over that found
in controls, with 5-DACTHF. Treatment of spheroids with 5-DACTHF in t
he presence of 1 muM hypoxanthine resulted in no significant reversal
of growth inhibition; 50% reversal required 10 muM hypoxanthine. The s
pheroid studies were extended to in vivo studies examining the effects
of 5-DACTHF on established WiDr and colon 38 tumors. The results show
ed that, in contrast to melphalan, which produced cures and tumor regr
essions, 5-DACTHF produced reversible growth inhibition with no signif
icant regression of tumors. The results predict that clinical response
, typically measured by tumor regression, may be rare following single
agent therapy with inhibitors of de novo purine biosynthesis.